Acadia Pharmaceuticals (ACAD) Capital Expenditures Growth (5y) (2017 - 2026)
Acadia Pharmaceuticals (ACAD) Capital Expenditures Growth (5y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,861.65 Bn | 66,861.36 Bn | - |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.72 Bn | - |
| 3 | Akari Therapeutics | 1,071.19 Bn | 1,071.19 Bn | - |
| 4 | BeOne Medicines | 469.11 Bn | 464.32 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 123.03 Bn | 115.78 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.13 Bn | 61.37 Bn | 3.31 Bn |
| 7 | Belite Bio | 63.44 Bn | 63.44 Bn | - |
| 8 | Argenx Se | 55.97 Bn | 50.78 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.53 Bn | 34.52 Bn | 959.66 Mn |
| 10 | Acadia Pharmaceuticals | 4.33 Bn | 3.48 Bn | 243.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 37.10% |
| Dec 31, 2025 | 14.91% |
| Sep 30, 2025 | -25.76% |
| Jun 30, 2025 | -36.75% |
| Dec 31, 2024 | 16.96% |
| Sep 30, 2024 | -2.64% |
| Dec 31, 2021 | -66.83% |
| Jun 30, 2021 | -40.03% |
| Mar 31, 2021 | 39.05% |
| Dec 31, 2020 | 46.82% |
| Sep 30, 2020 | 56.05% |
| Jun 30, 2020 | 34.19% |
| Mar 31, 2020 | -1.12% |
| Dec 31, 2019 | 17.10% |
| Sep 30, 2019 | 0.00% |
| Mar 31, 2019 | 167.51% |
| Dec 31, 2018 | 32.66% |
| Sep 30, 2018 | 19.53% |
| Jun 30, 2018 | 7.00% |
| Mar 31, 2018 | 125.26% |